Formulation and evaluation of the vascular endothelial growth factor loaded polycaprolactone nanoparticles
DOI:
https://doi.org/10.1590/s2175-97902022e19660%20%20Palavras-chave:
Nanoparticles, Polycaprolactone, VEGF, Double emulsion method, BioactivityResumo
In an attempt to increase molecular stability and provide controlled release, vascular endothelial growth factor (VEGF) was encapsulated into polycaprolactone (PCL) nanoparticles. Both VEGF-free and VEGF-loaded PCL nanoparticles were formulated by w/o/w double emulsion of the dichloromethane-water system in the presence of polyvinyl alcohol (PVA) and rat serum albumin. To achieve the optimal formulation concerning particle size and monodispersity, studies were carried out with different formulation parameters, including PVA concentration, homogenization time and rate. Scanning electron microscopy and dynamic light scattering analysis showed respectively that particles had a spherical shape with a smooth surface and particle size varying between 58.68-751.9 nm. All of the formulations were negatively charged according to zeta potential analysis. In vitro release study was performed in pH 7.4 phosphate-buffered saline at 37°C and released VEGF amount was measured by enzyme-linked immunosorbent assay (ELISA) method. At the end of the 35th day, 10% of total encapsulated VEGF was released with a sustained-release profile, which fitted the Korsmeyer-Peppas kinetic model. The bioactivation of the nanoparticles was evaluated using XTT and ELISA methods. As a result, the released VEGF was biologically active and also VEGF loaded PCL nanoparticles enhanced proliferation of the human umbilical vein endothelial cells in cell culture.
Downloads
Referências
Ahmed N, Michelin-Jamois M, Fessi H, Elaissari A. Modified double emulsion process as a new route to prepare submicron biodegradable magnetic/polycaprolactone particles for in vivo theranostics. Soft Matter. 2012;8:2554-64.
Alarçin E, Lee TY, Karuthedom S, Mohammadi M, Brennan MA, Lee DH, et al. Injectable shear-thinning hydrogels for delivering osteogenic and angiogenic cells and growth factors. Biomater Sci. 2018;6(6):1604-1615.
Alex AT, Joseph A, Shavi G, Rao JV, Udupa N. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv. 2016;23(7):2144-2153.
Bouissou C, Van der Walle C. Poly (lactic-co-glycolic acid) microsphere. In: Uchegbu JF, Schatzlein AG, editors. Polymers in drug delivery. Boca Raton, FL: CRC Press; 2006, p. 81-99.
Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336(2):367-375.
Bummer PM. Chemical consideration in protein and peptide stability. In: McNally EJ, Hastedt JE, editors. Protein Formulation and Delivery, 2nd edition. New York: Informa Healthcare; 2008, p. 7-42.
Dash TK, Konkimalla VB. Poly-ɛ-caprolactone based formulations for drug delivery and tissue engineering: A review. J Controlled Release. 2012;158(1):15-33.
De la Riva B, Nowak C, Sanchez E, Herandez A, Schulz-Siegmund M, Pec MK, et al. VEGF-controlled release within a bone defect from alginate/chitosan/PLA-H scaffolds. Eur J Pharm Biopharm. 2009;73(1):50-58.
Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res. 2006;312(5):522-526.
Ekentok C, Özbaş-Turan S, Akbuğa J. In vitro gene silencing effect of chitosan/shRNA PDGF-D nanoparticles in breast cancer. J Res Pharm. 2017;21(4):793-803.
Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002;72(1):20-32.
Eren F, Öksüz S, Küçükodacı Z, Kendirli MT, Cesur C, Alarçin E, et al. Targeted mesenchymal stem cell and vascular endothelial growth factor strategies for repair of nerve defects with nerve tissue implanted autogenous vein graft conduits. Microsurgery. 2015;36(7):578-585.
Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rew Drug Discov. 2004;3(5):391-400.
French KJ, Frazier KS. The role of VEGF and VEGF receptors in carcinogenesis. J Carcinog Mutagen. 2011;S2: 002.
Fruttiger M. VEGF Gene Regulation. In: Ruhrberg C, editor. VEGF in Development. Austin, Texas: Landes Bioscience; 2008, p. 30-39.
Golub JS, Kim Y, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol. 2010;298: H1959-H1965.
Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent evaporation techniques used for drug encapsulation. Int J Pharm . 2015;496(2):173-190.
Karagöz H, Ülkür E, Kerimoğlu O, Alarçin E, Şahin C, Akakın D, et al. Vascular endothelial growth factor loaded poly (lactic co glycolic acid) microspheres induced lateral axonal sprouting into the vein graft bridging two healthy nerves: Nerve graft prefabrication using controlled release system. Microsurgery. 2012;32(8):635-41.
Kaur M, Sharma S, Sinha VR. Polymer based microspheres of aceclofenac as sustained release parenterals for prolonged anti-inflammatory effect. Mater Sci Eng C. 2017;72:492-500.
Korsmeyer RW, Peppas NA. Effect of the morphology of hydrophilic polymeric matrices on the diffusion and release of water soluble drugs. J Membr Sci. 1981;9(3):211-227.
Kumar A, Sawant K. Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics. Cancer Nano. 2013;4(4-5):57-71.
Labet M, Thielemans W. Synthesis of polycaprolactone: a review. Chem Soc Rev. 2009;38(12):3484-3504.
Miladi K, Sfar S, Fessi H, Elaissari A. Nanoprecipitaion process: From particle preparation to in vivo applications. In: Vauthier C, Ponchel G, editors. Polymer Nanoparticles for Nanomedicines: A Guide for their Design, Preparation and Development. Switzerland: Springer; 2016, p. 17-53.
Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Progr Polym Sci. 2007;32(8-9):762-98.
Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110-111.
Ribeiro AF, Rezende R, Cabral LM, Sousa VP. Poly ɛ-caprolactone nanoparticles loaded with Uncaria tomentosa extract: preparation, characterization, and optimization using the Box-Behnken design. Int J Nanomed. 2013;8:431-442.
Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ, Windebank AJ, et al. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: In vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomater. 2012;8(2):511-518.
Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol. 2001;37(2):616-623.
Shibuya M. Vascular endothelial growth factor (VEGF)-receptor2: Its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006;13(2):63-69.
Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods. 2006;38(2):96-105.
Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int J Pharm . 2004;278(1):1-23.
Sipahigil O, Alarçin E, Türkoğlu M, Dortunç B, Karagöz H, Ülkür E, et al. Characterization, cell proliferation and cytotoxicity evaluation of vascular endothelial growth factor loaded poly (lactic-co-glycolic acid) microspheres. Nobel Medicus. 2012;8(1):77-82.
Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5(3):203-220.
Van de Weert M, Hoechstetter J, Hennink WE, Crommelin DJ. The effect of a water/organic solvent interface on the structural stability of lysozyme. J Controlled Release . 2000;68(3):351-9.
Verheyen A, Peeraer E, Lambrechts D, Poesen K, Carmeliet P, Shibuya M, et al. Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience. 2013;244:77-89.
Wisniewska M, Ostolska I, Szewczuk-Karpisz K, Chibowski S, Terpilowski K, Gun'ko VM, et al. Investigation of the polyvinyl alcohol stabilization mechanism and adsorption properties on the surface of ternary mixed nanooxide AST 50 (Al2O3-SiO2-TiO2). J Nanopart Res. 2015;17(1):12.
Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27(1):1-12.
Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol . 2007;49(10):1015-26.
Zhou M, Shen L, Lin X, Hong Y and Feng Y. Design and pharmaceutical applications of porous particles. RSC Adv. 2017;7:39490-39501.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
Como Citar
Dados de financiamento
-
Marmara Üniversitesi
Números do Financiamento SAG-B-130515-0157
